EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

Giacomo Ruotolo iD, Charles Harris, Yanzhu Lin, Jonathan M Wilson, Valentina Pirro, Kevin L Duffin, Melissa K Thomas iD, Mark L Hartman, Ciara O' Neill, Tamer Coskun iD, Zvonko Milicevic, Axel Haupt iD und 2 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71200 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Giacomo Ruotolo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly & Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Recombinant Fusion Proteins, Glucagon-Like Peptides. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials. In Study 1, adults with obesity/overweight and T2D received once‐weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks. Fasting blood samples were collected at baseline and during treatment to assess lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers. Mixed models for repeated measures estimated placebo‐adjusted change from baseline. Statistical significance was defined as a false discovery rate‐adjusted p < 0.05.

Results

Mean body mass index was 35.4 kg/m 2 (Study 1) and 37.4 kg/m 2 (Study 2). In both studies, retatrutide was associated with significant reductions in non‐high‐density lipoprotein cholesterol (Study 1: up to −21.0%, Study 2: up to −26.9%), apolipoprotein B (−21.4%, −24.2%), total triglyceride‐rich lipoprotein particles (−22.5%, −33.7%), large triglyceride‐rich lipoprotein particles (−84.4%, −76.6%), triglyceride‐rich lipoprotein cholesterol (−29.4%, −38.6%), total low‐density lipoprotein particles (−19.7%, −23.5%) and small low‐density lipoprotein particles (−32.6%, −32.3%). Retatrutide was associated with significant reductions in high‐sensitivity C‐reactive protein (−54.8%) and interleukin‐6 (−29.6%) in Study 2 but not Study 1.

Conclusions

In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk. Trial Registration: ClinicalTrials.gov numbers NCT04881760 and NCT04867785

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityRecombinant Fusion ProteinsGlucagon-Like PeptidesCardiovascular DiseasesHypoglycemic AgentsHumansFemaleMaleMiddle AgedBiomarkersDouble-Blind MethodAdultHeart Disease Risk FactorsLipoproteinsAgedFatty AcidsImmunoglobulin Fc FragmentsPeptides

Stichwörter der Autor:innen

antidiabetic drugantiobesity drugcardiovascular diseaseclinical trialincretin therapylipid‐lowering therapy

Substanzen

BiomarkersRecombinant Fusion ProteinsGlucagon-Like PeptidesdulaglutideHypoglycemic AgentsLipoproteinsretatrutideFatty AcidsImmunoglobulin Fc FragmentsPeptides

Autor:innen und Institutionen

  • Eli Lilly & Company, Indianapolis, Indiana, USA.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Giacomo Ruotolo, Melissa K Thomas, Tamer Coskun, Axel Haupt, Naveed Sattar

Förderung

  • Eli Lilly and Company

Zitieren

APA

Ruotolo, G., Harris, C., Lin, Y., Wilson, J. M., Pirro, V., Duffin, K. L., Thomas, M. K., Hartman, M. L., Neill, C. O., Coskun, T., Milicevic, Z., Haupt, A., Sattar, N., & Nicholls, S. J. (2026). Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71200

Vancouver

Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, et al. Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71200

BibTeX
@article{Ruotolo2026,
  author = {Ruotolo, Giacomo and Harris, Charles and Lin, Yanzhu and Wilson, Jonathan M and Pirro, Valentina and Duffin, Kevin L and Thomas, Melissa K and Hartman, Mark L and Neill, Ciara O' and Coskun, Tamer and Milicevic, Zvonko and Haupt, Axel and Sattar, Naveed and Nicholls, Stephen J},
  title = {Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71200}
}
Kostenlos starten →